Jonathan Polikoff
Medical Oncology · Longview, WANPI 1497822332
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Hoffmann-la Roche Limited at 27.7% of the total. Reporting peaked in 2019 at $3,173 and has fallen 76.3% since, to $753 in 2025.
Across 27 payments — averaging $205.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Hoffmann-la Roche Limited$2K
- F. Hoffmann-la Roche AG$2K
- Johnson & Johnson$387
- Daiichi Sankyo Inc.$350
- Karyopharm Therapeutics Inc.$244
- Pfizer$234
- plus $1K from 10 others
Across 59 payments — averaging $14,946 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$535K
- Genentech, Inc.$182K
- Eli Lilly$84K
- Seagen Inc.$38K
- Medivation LLC.$26K
- Merck$14K
- plus $2K from 1 others
What the payments were for
- Speaking & faculty fees$1,51327%
- Travel & lodging$1,15421%
- Food & beverage$2,87452%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Hoffmann-la Roche Limited | 3 | $1,532 |
| F. Hoffmann-la Roche AG | 3 | $1,513 |
| Johnson & Johnson | 3 | $387 |
| Daiichi Sankyo Inc. | 3 | $350 |
| Karyopharm Therapeutics Inc. | 2 | $244 |
| Pfizer | 2 | $234 |
| Sanofi | 2 | $220 |
| Jazz Pharmaceuticals Inc. | 1 | $141 |
| Exelixis Inc. | 1 | $132 |
| Portola Pharmaceuticals, LLC | 1 | $128 |
| Bayer | 1 | $125 |
| AbbVie | 1 | $124 |
| Blueprint Medicines Corporation | 1 | $123 |
| Eisai Inc. | 1 | $122 |
| Mirati Therapeutics, Inc. | 1 | $114 |
| Servier Pharmaceuticals LLC | 1 | $51 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,541 in reported general payments places this provider in the 60th percentile of 162 medical oncology providers in Washington.
Other medical oncology in Longview
- Hakan KayaSpokane$2.2M
- Bart ScottSeattle$1.3M
- William BensingerLakewood$1.2M
- Petros GrivasSeattle$628K
- Vijayakrishna GadiSeattle$573K
- Evan YuSeattle$296K
- Siddhartha DevarakondaSeattle$215K
- David MaloneySeattle$150K
- Gary LymanSeattle$130K
- Joseph YeOlympia$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.